This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thoratec's CEO Discusses Q4 2011 Results - Earnings Call Transcript

With respect to our financial results for the quarter, Thoratec generated revenues of $109.4 million, a 12% increase over revenues of $97.6 million in the fourth quarter of 2010. In terms of geographic breakdown, we reported revenues of $88.2 million in the U.S. versus $78.8 million in the prior year, an increase of 12%. While international revenues were $21.2 million versus $18.8 million a year ago, representing an increase of 13%. The year-over-year impact of foreign exchange was roughly neutral.

For the full year, revenues from continuing operations in 2011 were $422.7 million representing the high end of our previously issued revenue guidance, and a 10% increase relative to revenues of $383 million in 2010. The HeartMate and CentriMag product lines drove growth for the full year and populated revenues grew 13% offsetting more modest growth in non-pump revenues of 5%.

We also continue to demonstrate solid operating leverage with 2011 non-GAAP earnings per share rising $1.56 slightly above the high end of our previous guidance, and representing a 27% increase compared to 2010. We achieved this profitability increase through revenue growth and impressive gross margin expansion of over 300 basis points, while we continue to invest aggressively in our markets and product development initiatives.

Revenue growth in the fourth quarter was also led by our HeartMate and CentiMag product lines partially offset by a decline in sales of PVAD and IVAD. HeartMate revenues in the quarter were $93.8 million versus $83.9 million a year ago for an increase of 12%. Revenues from our acute surgical support line, which includes CentriMag and PediMag were $8.8 million compared with $5.7 million a year ago. This strong performance include a growth in the core U.S. CentriMag business of 10%, as well as approximately $2.5 million of incremental revenues recorded as a result of the transaction completed during the third quarter.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.66 -0.35%
FB $101.62 2.10%
GOOG $687.05 1.30%
TSLA $146.19 -1.40%
YHOO $27.27 1.70%


Chart of I:DJI
DOW 15,971.10 -43.28 -0.27%
S&P 500 1,867.53 +15.32 0.83%
NASDAQ 4,328.7440 +59.9810 1.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs